Drug Compounders Challenge FDA Removal of Semaglutide from Shortage List
- February 28, 2025
A trade group that represents outsourcing facilities is suing the Food and Drug Administration (FDA) to overturn its decision to remove semaglutide, the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy, from the agency’s drug shortage list.
ARTICLE TAGS
You must be logged in to access this content.